 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS...

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

This is a Bullish indicator signaling MRUS's price could rise from here. Traders may explore going long the stock or buying call options...

Merus (MRUS, $24.8) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 30, 2023

This indicator may be signaling MRUS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Merus (MRUS, $24.8) entered Uptrend as Momentum indicator ascends above 0 level on Nov 30, 2023

This indicator may be signaling that MRUS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Merus (MRUS, $23.58) entered Downtrend as Momentum indicator drops below 0 level on Nov 29, 2023

This is a Bearish indicator signaling MRUS's price could decline from here. Traders may explore shorting the stock or put options...

Merus (MRUS, $23.58) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 29, 2023

Needham  Company LLC restated their buy rating on shares of Merus (NASDAQ:MRUS  Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently...

Merus (NASDAQ:MRUS) Receives Buy Rating from Needham & Company LLC

- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in...

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Merus (MRUS, $23.64) entered Uptrend as Momentum indicator ascends above 0 level on Nov 22, 2023

Merus (MRUS, $23.66) entered Downtrend as Momentum indicator drops below 0 level on Nov 21, 2023

Merus (MRUS, $24.34) entered Uptrend as Momentum indicator ascends above 0 level on Nov 20, 2023

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Watchers	800
52-Wk Low	$12.44
52-Wk High	$27.70

Market Cap	$1.45B
Volume (M)	867,299.00
52-Wk High	$27.70
52-Wk Low	$12.44

MRUS Merus N.V

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community